目的在非HBV和非HCV感染肝癌(HCC)患者中探索影响肝癌患者生存的风险因素。方法选择328名自2010年1月至2012年12月在我院进行了肝切除治疗的原发性肝癌患者,其中非HBV和非HCV感染(NBNCHCC)组为69名肝癌患者,病毒性(HBV or HCV)HCC组为25...目的在非HBV和非HCV感染肝癌(HCC)患者中探索影响肝癌患者生存的风险因素。方法选择328名自2010年1月至2012年12月在我院进行了肝切除治疗的原发性肝癌患者,其中非HBV和非HCV感染(NBNCHCC)组为69名肝癌患者,病毒性(HBV or HCV)HCC组为259名肝癌患者。收集肝癌病人的基线临床信息并随访至术后五年的生存状况。两组间术后生存期的比较使用Kaplan-Meier方法,采用多变量Cox比例风险模型评估影响NBNC-HCC肝癌预后独立的因素。结果 NBNC-HCC和病毒性HCC患者间五年总生存期的生存曲线虽并无统计学差异性(Log-rank Chi square=3.45,P=0.063),但在随访三年后,生存期已呈现差异趋势。两组间无癌生存曲线的比较显示,NBNC-HCC患者比病毒性HCC患者有更长的无癌生存期(Log-rank Chi square=15.65,P<0.001)。多变量Cox比例回归分析发现肝脏疾病状态(肝硬化和慢性肝炎患者对比肝相对正常患者),癌细胞血管浸润(阳性对比阴性患者)、病理分级(从Ⅰ到Ⅳ级)均为导致NBNC-HCC患者总生存期降低的危险因素,死亡风险分别增加0.31、0.49和0.19倍。细胞血管浸润(阳性对比阴性患者)、病理分级(从Ⅰ到Ⅳ级)可降低NBNC-HCC患者无癌生存期,风险分别增加0.43和0.17倍。结论 NBNC-HCC比病毒性HCC患者有更长的五年无癌生存期,肝癌细胞血管浸润和高级别病理分级均为导致NBNC-HCC患者总生存期和无癌生存期降低的风险因素。展开更多
Background:Adjuvant(chemo)radiotherapy(A(C)RT)may be an important supplement to surgery for extrahepatic cholangiocarcinoma(EHCC).However,whether all patients would achieve benefits from A(C)RT and which adjuvant regi...Background:Adjuvant(chemo)radiotherapy(A(C)RT)may be an important supplement to surgery for extrahepatic cholangiocarcinoma(EHCC).However,whether all patients would achieve benefits from A(C)RT and which adjuvant regimen,adjuvant radiotherapy(ART)or adjuvant chemoradiotherapy(ACRT),would be preferred,are still undetermined.The low incidence of EHCC makes it difficult to carry out randomized controlled trials(RCTs);therefore,almost all clinical studies on radiotherapy are retrospective.We have conducted a meta-analysis of these retrospective studies.Methods:We conducted a meta-analysis of current retrospective studies using PubMed,Embase,and ClinicalTrials databases.All studies published in English that were related to A(C)RT and which analyzed overall survival(OS),disease-free survival(DFS),or locoregional recurrence-free survival(LRFS)were included.Estimated hazard ratios(HRs)were calculated for OS,DFS,and LRFS.Results:Data from eight studies including 685 patients were included.Our analysis showed that A(C)RT significantly improved OS(HR 0.69,95%confidence interval(CI)0.48–0.97,P=0.03),DFS(HR 0.60,95%CI 0.47–0.76,P<0.0001),and LRFS(HR 0.27,95%CI 0.17–0.41,P<0.00001)of EHCC overall.In subgroups,patients with microscopically positive resection margin(R1)could achieve a benefit from A(C)RT(HR 0.44,95%CI 0.27–0.72,P=0.001).No statistically OS difference was observed in negative resection margin(R0)subgroup(HR 0.98,95%CI 0.30–3.19,P=0.98).Significant OS benefit was found in patients who received concurrent ACRT(HR 0.40,95%CI 0.26–0.62,P<0.0001),while the result of ART without chemotherapy showed no significant benefit(HR 1.14,95%CI 0.29–4.50,P=0.85).In the distal cholangiocarcinoma subgroup,no significant difference was seen when ACRT and ART were included(HR 0.61,95%CI 0.14–2.72,P=0.52),but a significant difference was seen ewOshSpe,enDc iaFanlSla,yl yianzn iddn igsL ttRahlF ep Sca iotinne cEnutHrsr.C eCnt pAaCtieRnTt so,nelys p(eHcRi a0 ll.y2 i9 n,t9 h5 o%s eC Iw i0 t.h13 R–10 r.e6 s4 e,cPti=o0 n.0 m0 a2 r).g iCnso.n AclCusRioT nms:aAy(bCe)RsTu pmeraiyo ri tmop rAoRvTe .展开更多
文摘目的在非HBV和非HCV感染肝癌(HCC)患者中探索影响肝癌患者生存的风险因素。方法选择328名自2010年1月至2012年12月在我院进行了肝切除治疗的原发性肝癌患者,其中非HBV和非HCV感染(NBNCHCC)组为69名肝癌患者,病毒性(HBV or HCV)HCC组为259名肝癌患者。收集肝癌病人的基线临床信息并随访至术后五年的生存状况。两组间术后生存期的比较使用Kaplan-Meier方法,采用多变量Cox比例风险模型评估影响NBNC-HCC肝癌预后独立的因素。结果 NBNC-HCC和病毒性HCC患者间五年总生存期的生存曲线虽并无统计学差异性(Log-rank Chi square=3.45,P=0.063),但在随访三年后,生存期已呈现差异趋势。两组间无癌生存曲线的比较显示,NBNC-HCC患者比病毒性HCC患者有更长的无癌生存期(Log-rank Chi square=15.65,P<0.001)。多变量Cox比例回归分析发现肝脏疾病状态(肝硬化和慢性肝炎患者对比肝相对正常患者),癌细胞血管浸润(阳性对比阴性患者)、病理分级(从Ⅰ到Ⅳ级)均为导致NBNC-HCC患者总生存期降低的危险因素,死亡风险分别增加0.31、0.49和0.19倍。细胞血管浸润(阳性对比阴性患者)、病理分级(从Ⅰ到Ⅳ级)可降低NBNC-HCC患者无癌生存期,风险分别增加0.43和0.17倍。结论 NBNC-HCC比病毒性HCC患者有更长的五年无癌生存期,肝癌细胞血管浸润和高级别病理分级均为导致NBNC-HCC患者总生存期和无癌生存期降低的风险因素。
基金Project supported by the National Natural Science Foundation of China(No.81402520)。
文摘Background:Adjuvant(chemo)radiotherapy(A(C)RT)may be an important supplement to surgery for extrahepatic cholangiocarcinoma(EHCC).However,whether all patients would achieve benefits from A(C)RT and which adjuvant regimen,adjuvant radiotherapy(ART)or adjuvant chemoradiotherapy(ACRT),would be preferred,are still undetermined.The low incidence of EHCC makes it difficult to carry out randomized controlled trials(RCTs);therefore,almost all clinical studies on radiotherapy are retrospective.We have conducted a meta-analysis of these retrospective studies.Methods:We conducted a meta-analysis of current retrospective studies using PubMed,Embase,and ClinicalTrials databases.All studies published in English that were related to A(C)RT and which analyzed overall survival(OS),disease-free survival(DFS),or locoregional recurrence-free survival(LRFS)were included.Estimated hazard ratios(HRs)were calculated for OS,DFS,and LRFS.Results:Data from eight studies including 685 patients were included.Our analysis showed that A(C)RT significantly improved OS(HR 0.69,95%confidence interval(CI)0.48–0.97,P=0.03),DFS(HR 0.60,95%CI 0.47–0.76,P<0.0001),and LRFS(HR 0.27,95%CI 0.17–0.41,P<0.00001)of EHCC overall.In subgroups,patients with microscopically positive resection margin(R1)could achieve a benefit from A(C)RT(HR 0.44,95%CI 0.27–0.72,P=0.001).No statistically OS difference was observed in negative resection margin(R0)subgroup(HR 0.98,95%CI 0.30–3.19,P=0.98).Significant OS benefit was found in patients who received concurrent ACRT(HR 0.40,95%CI 0.26–0.62,P<0.0001),while the result of ART without chemotherapy showed no significant benefit(HR 1.14,95%CI 0.29–4.50,P=0.85).In the distal cholangiocarcinoma subgroup,no significant difference was seen when ACRT and ART were included(HR 0.61,95%CI 0.14–2.72,P=0.52),but a significant difference was seen ewOshSpe,enDc iaFanlSla,yl yianzn iddn igsL ttRahlF ep Sca iotinne cEnutHrsr.C eCnt pAaCtieRnTt so,nelys p(eHcRi a0 ll.y2 i9 n,t9 h5 o%s eC Iw i0 t.h13 R–10 r.e6 s4 e,cPti=o0 n.0 m0 a2 r).g iCnso.n AclCusRioT nms:aAy(bCe)RsTu pmeraiyo ri tmop rAoRvTe .
